BR9607752B1 - controlled release microcapsule pharmaceutical formulation. - Google Patents

controlled release microcapsule pharmaceutical formulation.

Info

Publication number
BR9607752B1
BR9607752B1 BRPI9607752-2A BR9607752A BR9607752B1 BR 9607752 B1 BR9607752 B1 BR 9607752B1 BR 9607752 A BR9607752 A BR 9607752A BR 9607752 B1 BR9607752 B1 BR 9607752B1
Authority
BR
Brazil
Prior art keywords
controlled release
pharmaceutical formulation
release microcapsule
microcapsule pharmaceutical
formulation
Prior art date
Application number
BRPI9607752-2A
Other languages
Portuguese (pt)
Other versions
BR9607752A (en
Inventor
Ramasubbu Jeyanthi
Hamont John F Van
Phil Friden
Robert H Reid
F Donald Roberts
Charles E Mcqueen
Jean A Setterstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25744089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9607752(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9607752A publication Critical patent/BR9607752A/en
Publication of BR9607752B1 publication Critical patent/BR9607752B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI9607752-2A 1996-01-24 1996-11-18 controlled release microcapsule pharmaceutical formulation. BR9607752B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59097396A 1996-01-24 1996-01-24
PCT/US1996/019440 WO1997026869A1 (en) 1996-01-24 1996-11-18 Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
CNB961947683A CN100391445C (en) 1996-01-24 1996-11-18 Novel 'burst-free' sustained release poly-(lactide/glycolide) mi crospheres

Publications (2)

Publication Number Publication Date
BR9607752A BR9607752A (en) 1999-11-30
BR9607752B1 true BR9607752B1 (en) 2009-05-05

Family

ID=25744089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9607752-2A BR9607752B1 (en) 1996-01-24 1996-11-18 controlled release microcapsule pharmaceutical formulation.

Country Status (8)

Country Link
EP (1) EP0817619A4 (en)
JP (1) JPH11509862A (en)
CN (1) CN100391445C (en)
AP (1) AP665A (en)
AU (1) AU722884B2 (en)
BR (1) BR9607752B1 (en)
NZ (1) NZ325561A (en)
WO (1) WO1997026869A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033608B1 (en) * 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
AR012448A1 (en) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech COMPOSITION IN THE FORM OF MICROCAPSULES OR IMPLANTS COMPRISING A BIODEGRADABLE CONTAINER, POLYMER OR CO-POLYMER, OR A MIXTURE OF SUCH EXCIPIENTS, AND AN ACTIVE SUBSTANCE OR MIXTURE OF ACTIVE SUBSTANCES, PROCEDURE FOR THE PREPARATION OF A SUBSTANCE IN A SUBSTANCE
CN1075945C (en) * 1998-02-26 2001-12-12 中国科学院化学研究所 High-polymer encapsulated insulin microsome and its preparation method and use
CN1073412C (en) * 1998-03-19 2001-10-24 中国科学院化学研究所 Method for prepn. of macromolecule microcapsule
US7217770B2 (en) * 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
JP2004514702A (en) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド Intraocular implant for preventing transplant rejection in the eye
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
CN101007169B (en) * 2006-01-23 2011-05-25 珠海市嘉族生物科技有限公司 A microcapsule of egg yolk immunoglobulin, preparing process and use thereof
KR100816065B1 (en) 2006-11-27 2008-03-24 동국제약 주식회사 Preparation method of sustained-release microcapsules having good initial burst inhibiting property and the microcapsules thereby
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
CN101612111B (en) * 2008-06-24 2011-11-23 上海医药工业研究院 Sustained-release microsphere of nomegestrol acetate of analogs thereof and preparation method and application thereof
KR20100037389A (en) * 2008-10-01 2010-04-09 연세대학교 산학협력단 Solid microstructure with multi-controlled release and process for preparing the same
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN102357080B (en) * 2011-11-04 2014-07-16 无锡中科光远生物材料有限公司 Intelligent multifunctional hollow microsphere capable of quickly releasing medicine in acid environment and preparation method for intelligent multifunctional hollow microsphere
US10675376B2 (en) 2012-05-24 2020-06-09 Ethicon Llc Mechanically strong absorbable polymeric blend compositions of precisely controllable absorption rates, processing methods, and products therefrom
HUE036141T2 (en) * 2013-06-20 2018-06-28 Pharmathen Sa Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
US20170022256A1 (en) * 2015-07-23 2017-01-26 General Biologicals Corporation Anti-fungal and anti-bacterial peptide and therapeutic method using same
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN113384536B (en) * 2020-03-14 2024-04-02 鲁南制药集团股份有限公司 Sustained release galanthamine pamoate particles for injection and preparation method thereof
CN115025290A (en) * 2022-06-15 2022-09-09 浙江天妍生物科技有限公司 Degradable microsphere and production process thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
DE4005415C2 (en) * 1990-02-21 1996-04-11 Boehringer Ingelheim Kg Process for the preparation of polyesters based on hydroxycarboxylic acids
EP0463194A1 (en) * 1990-06-23 1992-01-02 Boehringer Ingelheim Kg Process for the preparation of poly(D,L-lactide) and its use as a drug carrier
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
DE4235312A1 (en) * 1991-10-23 1993-04-29 Boehringer Ingelheim Kg Semi-solid mixts. of D- or L-lactic acid oligomer or polymer - used e.g. as resorbable implants, or bone waxes
JPH09504523A (en) * 1993-10-22 1997-05-06 ジェネンテク，インコーポレイテッド Adjuvant microencapsulation methods and compositions
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
DE19513659A1 (en) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Microparticle formulations of aggregation-sensitive polypeptides

Also Published As

Publication number Publication date
NZ325561A (en) 1999-06-29
AP9701088A0 (en) 1997-10-31
CN100391445C (en) 2008-06-04
AP665A (en) 1998-08-19
JPH11509862A (en) 1999-08-31
AU722884B2 (en) 2000-08-10
CN1188408A (en) 1998-07-22
AU1410497A (en) 1997-08-20
EP0817619A4 (en) 1999-02-03
EP0817619A1 (en) 1998-01-14
WO1997026869A1 (en) 1997-07-31
BR9607752A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
BR9607752B1 (en) controlled release microcapsule pharmaceutical formulation.
IT1303444B1 (en) DRUG RELEASE DEVICE.
BR9713237B1 (en) Alfuzosine hydrochloride controlled release tablet and pharmaceutical composition comprising the same.
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
BR9701304A (en) Extended release formulation
DK0998272T3 (en) Pharmaceutical preparation for the combination piperidinoalkanol decongestant
TR199501560A2 (en) Gradually released caffeine formulation.
DZ2686A1 (en) Pulsed release oral pharmaceutical formulation.
NO20012636L (en) Controlled release formulation comprising GNRH-II
BR9805993B1 (en) aerosol pharmaceutical composition.
BR9607851B1 (en) combination and pharmaceutical formulation.
DK1109449T3 (en) Microcapsule formulations
NO981008D0 (en) Pharmaceutical formulation
BR9407725A (en) Active substance release system
ZA9810081B (en) Extended release formulation.
NO20001375L (en) Drug formulation with controlled release
BR9703689A (en) Perfume release system
DK1109450T3 (en) The microcapsule preparations
DE69821977D1 (en) LIQUID, INSECTICIDE FORMULATION FORMULATION
EE04045B1 (en) Micro-granules release the diltiazem continuously as the active ingredient
ID16781A (en) PHARMACEUTICAL FORMULATIONS
ATE237927T1 (en) SLOW RELEASE PESTICIDE FORMULATION
DZ1926A1 (en) Pharmaceutical formulations.
DE69717773D1 (en) Controlled release pesticide formulation
EE03511B1 (en) Prolonged release pharmaceutical preparations containing misolastin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061560/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132356-33.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: THE SECRETARY OF STATE FOR DEFENCE, THE WELLCOME FOUNDATION LIMITED, THERATECHNOLOGIES INC, UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY, UNIVERSITE DE MONTREAL.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061560/2013-54 SECAO JUDICIARIA DO RIO DE JANEIRO 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0132356-33.2013.4.02.5101APELADO: THE SECRETARY OF STATE FOR DEFENCE E OUTROS APELANTE: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: PELO EXPOSTO, DIVIRJO DO EXMO. RELATOR E DOU PROVIMENTO AO RECURSO DE APELACAO E JULGO PROCEDENTE O PEDIDO ALTERNATIVO, PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9508392-8, PI 9607850-2, PI 9607851-0, PI 9608799-4, PI 9607752-2 E PI 9510423-2, E DETERMINAR A CORRECAO DE SEUS RESPECTIVOS PRAZOS DE VIGENCIA CONFORME TABELA A SEGUIR:PATENTE: PI 9508392-8 NOVO PRAZO DE VIGENCIA: 12/07/2015PATENTE: PI 9607850-2 NOVO PRAZO DE VIGENCIA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A PUBLICACAO NA RPI 2000 DE 05.05.2009, QUANTO AO PRAZO DE VIGENCIA: ATE 18.11.2016, CONFORME DECISAO JUDICIAL PUBLICADA NA RPI 2547 DE 29.10.2019 - INPI 52400.061560/2013